FGL1 Protein Characterization for Cancer Detection

Part of the fibrinogen protein family, FGL1 is expressed at low levels in the liver under usual conditions. By contrast, this protein is highly expressed in various types of cancers such as melanoma and prostate cancer.

According to a recent study, FGL1 protein is a hot immune inhibitory ligand of LAG-3 products. Therefore, inhibiting the interaction between FGL1 and LAG-3 would not only improve the body’s immunity but would also slow down the growth of tumors.

ACROBiosystems has developed HEK293-expressed FGL1 protein with a wide range of tags (His, Fc) and species (Mouse, Human, Cyno). The company has also developed AviTagTM biotinylated FGL1 protein that can help in developing drugs. Moreover, ACROBiosystems has validated the activity and purity of FGL1 protein and also offers protocols.

Application

Product List

Molecule Cat. No. Host Product Description Product Status
FGL1
(HEK293 expressed)
FG1-H5253 Human Human FGL1 Protein, Fc Tag Launched
FG1-H82F3 Human Biotinylated Human FGL1 Protein, Fc Tag, Avi Tag (Avitag™)
FG1-M5255 Mouse Mouse FGL1 Protein, Fc Tag
FG1-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque FGL1 Protein, Fc Tag
FG1-H52H7 Human Human FGL1 Protein, His Tag Coming soon
FG1-H82E5 Human Biotinylated Human FGL1 Protein, His Tag, Avi Tag (Avitag™)
FG1-M5253 Mouse Mouse FGL1 Protein, Mouse IgG2a Fc Tag
FG1-C5256 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque FGL1 Protein, Mouse IgG2a Fc Tag

 

As cited above, FGL1 protein has been recognized as a hot immune inhibitory ligand of LAG-3 products.

Bioactivity

Bioactivity of FGL1 was Validated by ELISA

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 10 μg/mL (100 μL/well) can bind Biotinylated Human FGL1, Fc Tag, Avi Tag (Cat. No. FG1-H82F3) with a linear range of 0.156–1.25 μg/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 10 μg/mL (100 μL/well) can bind Biotinylated Human FGL1, Fc Tag, Avi Tag (Cat. No. FG1-H82F3) with a linear range of 0.156–1.25 μg/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 20 μg/mL (100 μL/well) can bind Human FGL1, Fc Tag (Cat. No. FG1-H5253) with a linear range of 5–78 ng/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 20 μg/mL (100 μL/well) can bind Human FGL1, Fc Tag (Cat. No. FG1-H5253) with a linear range of 5–78 ng/mL.

Immobilized Mouse LAG-3, His Tag (Cat. No. LA3-M52H5) at 20 μg/mL (100 μL/well) can bind Mouse FGL1, Fc Tag (Cat. No. FG1-M5255) with a linear range of 0.078–1.25 μg/mL.

Immobilized Mouse LAG-3, His Tag (Cat. No. LA3-M52H5) at 20 μg/mL (100 μL/well) can bind Mouse FGL1, Fc Tag (Cat. No. FG1-M5255) with a linear range of 0.078–1.25 μg/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque FGL1, Fc Tag (Cat. No. FG1-C5253) with a linear range of 8–125 ng/mL.

Immobilized Human LAG-3, mouse IgG2a Fc tag (Cat. No. LA3-H52Aa) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque FGL1, Fc Tag (Cat. No. FG1-C5253) with a linear range of 8–125 ng/mL.

*Customers can contact ACROBiosystems if they wish to add further experimental design and application data of FGL1 protein. If they have any custom-made product or more suggestion for FGL1 protein, they can explore the development suggestion section.

About ACROBiosystems

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application oriented development strategy, with a particular focus on product design, quality control and solution based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.

To respond to coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantity.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Aug 24, 2020 at 8:14 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2020, August 24). FGL1 Protein Characterization for Cancer Detection. News-Medical. Retrieved on December 05, 2020 from https://www.news-medical.net/whitepaper/20190814/FGL1-Protein-Characterization-for-Cancer-Detection.aspx.

  • MLA

    ACROBiosystems. "FGL1 Protein Characterization for Cancer Detection". News-Medical. 05 December 2020. <https://www.news-medical.net/whitepaper/20190814/FGL1-Protein-Characterization-for-Cancer-Detection.aspx>.

  • Chicago

    ACROBiosystems. "FGL1 Protein Characterization for Cancer Detection". News-Medical. https://www.news-medical.net/whitepaper/20190814/FGL1-Protein-Characterization-for-Cancer-Detection.aspx. (accessed December 05, 2020).

  • Harvard

    ACROBiosystems. 2020. FGL1 Protein Characterization for Cancer Detection. News-Medical, viewed 05 December 2020, https://www.news-medical.net/whitepaper/20190814/FGL1-Protein-Characterization-for-Cancer-Detection.aspx.

Other White Papers by this Supplier